➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Baxter
AstraZeneca
Express Scripts
Medtronic

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,536,130


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,536,130 protect, and when does it expire?

Patent 8,536,130 protects NUCYNTA ER and is included in one NDA.

This patent has eighteen patent family members in twelve countries.

Summary for Patent: 8,536,130
Title:Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain
Abstract: Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.
Inventor(s): Christoph; Thomas (Aachen, DE), Friderichs; Elmar (Stolberg, DE), Koegel; Babette-Yvonne (Langerwehe-Hamich, DE), Meen; Murielle (Ayguesvives, FR)
Assignee: Gruenenthal GmbH (Aachen, DE)
Application Number:12/850,208
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,536,130
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,536,130

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Collegium Pharm Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-001 Aug 25, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY ⤷  Free Forever Trial
Collegium Pharm Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-002 Aug 25, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY ⤷  Free Forever Trial
Collegium Pharm Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-003 Aug 25, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY ⤷  Free Forever Trial
Collegium Pharm Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-004 Aug 25, 2011 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY ⤷  Free Forever Trial
Collegium Pharm Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-005 Aug 25, 2011 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,536,130

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2007 012 165Mar 12, 2007

International Family Members for US Patent 8,536,130

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2680771 ⤷  Free Forever Trial
Cyprus 1115455 ⤷  Free Forever Trial
Germany 102007012165 ⤷  Free Forever Trial
Denmark 2117525 ⤷  Free Forever Trial
European Patent Office 2117525 ⤷  Free Forever Trial
Spain 2452830 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Medtronic
Dow
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.